Literature DB >> 15716550

4-aminopyridine restores visual ocular motor function in upbeat nystagmus.

S Glasauer1, R Kalla, U Büttner, M Strupp, T Brandt.   

Abstract

The effect of the potassium channel blocker 4-aminopyridine (4-AP) on spontaneous upbeat nystagmus (UBN) was investigated with the search coil technique during fixation in different gaze positions and smooth pursuit in a patient before and after ingestion of 10 mg 4-AP. UBN was reduced from 8.6 deg/s to 2.0 deg/s by 4-AP causing subjective relief from distressing oscillopsia, and impaired upward smooth pursuit was restored (gains: before medication 0.38; after medication 0.86). In the dark, UBN was slightly stronger and not affected by 4-AP. We propose that 4-AP improved the function of cerebellar pathways that mediate gaze holding and smooth pursuit by intensifying the excitability of cerebellar Purkinje cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15716550      PMCID: PMC1739571          DOI: 10.1136/jnnp.2004.045716

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

1.  Treatment of nystagmus.

Authors:  Matthew J Thurtell; R John Leigh
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.598

Review 2.  What we know about the generation of nystagmus and other ocular oscillations: are we closer to identifying therapeutic targets?

Authors:  Rebecca Jane McLean; Irene Gottlob; Frank Antony Proudlock
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

3.  Current treatment of vestibular, ocular motor disorders and nystagmus.

Authors:  Michael Strupp; Thomas Brandt
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

4.  KCa channels as therapeutic targets in episodic ataxia type-2.

Authors:  Karina Alviña; Kamran Khodakhah
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

5.  The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.

Authors:  Karina Alviña; Kamran Khodakhah
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

6.  Transition from downbeat to upbeat nystagmus caused by 4-aminopyridine.

Authors:  K Feil; J Claaßen; S Bardins; J Teufel; M Habs; R Kalla; M Strupp
Journal:  J Neurol       Date:  2013-04-18       Impact factor: 4.849

Review 7.  The physiological basis of therapies for cerebellar ataxias.

Authors:  Hiroshi Mitoma; Mario Manto
Journal:  Ther Adv Neurol Disord       Date:  2016-05-20       Impact factor: 6.570

Review 8.  Current Opinions and Consensus for Studying Tremor in Animal Models.

Authors:  Sheng-Han Kuo; Elan D Louis; Phyllis L Faust; Adrian Handforth; Su-Youne Chang; Billur Avlar; Eric J Lang; Ming-Kai Pan; Lauren N Miterko; Amanda M Brown; Roy V Sillitoe; Collin J Anderson; Stefan M Pulst; Martin J Gallagher; Kyle A Lyman; Dane M Chetkovich; Lorraine N Clark; Murni Tio; Eng-King Tan; Rodger J Elble
Journal:  Cerebellum       Date:  2019-12       Impact factor: 3.847

9.  Diagnosis and treatment of vertigo and dizziness.

Authors:  Michael Strupp; Thomas Brandt
Journal:  Dtsch Arztebl Int       Date:  2008-03-07       Impact factor: 5.594

10.  [Vertigo and dizziness: the neurologist's perspective].

Authors:  M Strupp
Journal:  Ophthalmologe       Date:  2013-01       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.